SiBone (NASDAQ:SIBN - Get Free Report) SVP Michael A. Pisetsky sold 3,127 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $18.29, for a total transaction of $57,192.83. Following the transaction, the senior vice president owned 261,681 shares of the company's stock, valued at $4,786,145.49. This trade represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
SiBone Price Performance
Shares of NASDAQ SIBN traded down $0.46 during mid-day trading on Monday, reaching $18.01. 344,646 shares of the company were exchanged, compared to its average volume of 395,174. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The company has a quick ratio of 7.26, a current ratio of 8.53 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $767.59 million, a PE ratio of -28.14 and a beta of 0.93. The company's 50 day moving average price is $17.89 and its 200 day moving average price is $16.23.
SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SiBone had a negative net margin of 15.03% and a negative return on equity of 16.00%. The company had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. Sell-side analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have recently commented on the stock. Truist Financial boosted their price target on shares of SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of SiBone in a research report on Tuesday, May 6th.
Read Our Latest Stock Analysis on SIBN
Institutional Trading of SiBone
A number of hedge funds have recently made changes to their positions in the stock. Proficio Capital Partners LLC bought a new stake in SiBone in the fourth quarter worth $155,000. Charles Schwab Investment Management Inc. lifted its stake in SiBone by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 321,263 shares of the company's stock worth $4,504,000 after purchasing an additional 6,171 shares during the last quarter. Raymond James Financial Inc. bought a new stake in SiBone in the fourth quarter worth $1,233,000. AlphaQuest LLC lifted its stake in SiBone by 13,950.6% in the fourth quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock worth $164,000 after purchasing an additional 11,579 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its stake in SiBone by 24.3% in the fourth quarter. Essex Investment Management Co. LLC now owns 208,160 shares of the company's stock worth $2,918,000 after purchasing an additional 40,636 shares during the last quarter. 98.11% of the stock is owned by institutional investors.
About SiBone
(
Get Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SiBone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.
While SiBone currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.